Mentholatum Issues Nationwide Recall of Rohto Eye Drops
Mentholatum announces a voluntary nationwide recall of Rohto Eye Drops made in Vietnam.
Mentholatum, a manufacturer of pharmaceuticals, and other healthcare products, is conducting a voluntary recall to the retail level of eye drops made in Vietnam due to a manufacturing review at the production facility in Vietnam involving sterility controls.
The recall includes only lots of Rohto Arctic, Rohto Ice, Rohto Hydra, Rohto Relief, and Rohto Cool eye drops that were manufactured in Vietnam and does not include eye drops made in Japan. Products manufactured in Japan are not included in this recall and continue to be available to consumers.
To date, there has been no evidence indicating that product does not meet specifications; however, the company is taking this action as a precautionary measure.
Source: Mentholatum
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
